Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(15):1099-1101; doi:10.1093/jnci/djg013
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Laskin, J.
Right arrow Articles by Johnson, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laskin, J.
Right arrow Articles by Johnson, D. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

EDITORIAL

An Advance in Small-Cell Lung Cancer Treatment—More or Less

Janessa Laskin, Alan Sandler, David H. Johnson

Affiliations of authors: J. Laskin, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada; A. Sandler, D. H. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN.

Correspondence to: David H. Johnson, MD, Division of Hematology and Oncology, Vanderbilt-Ingram Comprehensive Cancer Center, 2220 Pierce Ave., Nashville, TN 37232–6307 (e-mail: david.h.johnson@vanderbilt.edu).

The first 10% of the full text of this article appears below.

Although small-cell lung cancer (SCLC) once constituted 20%–25% of all newly diagnosed lung cancers in North America, in recent years the incidence has decreased to less than 15% (1,2). Nonetheless, deaths resulting from SCLC remain substantial and represent a major public health concern both in the United States and abroad. Fortunately, SCLC is a moderately chemo-sensitive neoplasm and, over the past three decades, considerable progress has been made in the management of this disease (3,4). In fact, even though cure remains elusive for most patients, median survival now approaches 2 years for patients with limited-stage disease and averages 9–10 months for patients with extensive-stage disease (5). In North America, SCLC is most commonly treated with a two-drug chemotherapy regimen consisting of cisplatin (or carboplatin) and etoposide (PE). Patients with limited-stage disease also . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
T. Gudermann and S. Roelle
Calcium-dependent growth regulation of small cell lung cancer cells by neuropeptides
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1069 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
Ann. Onc., November 1, 2005; 16(11): 1811 - 1816.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Tamborini, L. Bonadiman, T. Negri, A. Greco, S. Staurengo, P. Bidoli, U. Pastorino, M. A. Pierotti, and S. Pilotti
Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer
Clin. Cancer Res., December 15, 2004; 10(24): 8214 - 8219.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Heinrich
Is KIT an Important Therapeutic Target in Small Cell Lung Cancer?: Commentary re: B. E. Johnson et al., Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin. Cancer Res., 9: 5880-5887, 2003.
Clin. Cancer Res., December 1, 2003; 9(16): 5825 - 5828.
[Full Text] [PDF]